Cabaletta Bio, Inc. (NASDAQ: CABA) Stock Information | RedChip

Cabaletta Bio, Inc. (NASDAQ: CABA)


$2.3400
-0.0400 ( -2.50% ) 232.3K

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Market Data


Open


$2.3400

Previous close


$2.3800

Volume


232.3K

Market cap


$114.62M

Day range


$2.3050 - $2.4400

52 week range


$1.7600 - $26.3500

SEC Filings


Form Type Description Pages Date
8-k 8K-related 77 Nov 18, 2024
10-q Quarterly Reports 63 Nov 14, 2024
8-k 8K-related 13 Nov 14, 2024
8-k 8K-related 37 Oct 07, 2024
8-k 8K-related 11 Sep 30, 2024
10-q Quarterly Reports 57 Aug 08, 2024
8-k 8K-related 39 Aug 08, 2024
8-k 8K-related 85 Jun 14, 2024
4 Insider transactions 1 Jun 04, 2024
def Proxies and info statements 12 Apr 23, 2024

Latest News